Eleusis SPAC

Attractive Valuation Relative to Peers - Phase I Results May Drive Convergence Lead Candidate Formulation Indication Clinical Stage Drug Discovery Platform Care Delivery Services Enterprise Value (USD) eleusis ELE-Psilo (Psilocin) IV Major Depressive Disorder Anticipated Phase I Results in 2H 2022 $446M (Pro Forma Valuation) eleusis Enterprise value (USD) of Compass Pathways PLC (CMPS) and GH Research PLC (GHRS) as of January 14, 2022 COMPASSION Navigating Mental Health Pathways COMP360 (Psilocybin) Oral Treatment-Resistant Depression Phase II Completed $479M GH Research GH001 (5-MeO-DMT) Intranasal Treatment-Resistant Depression Phase I/II Completed $719M 30

View entire presentation